Next, we used the CD123+ CD47+ AML cell line MOLM-13 in a flow cytometry-based binding assay to study the dual targeting properties of the antibody constructs (Fig. 2A, Table 2). This evidence concerns the gene CD47 and acute myeloid leukemia.